Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Voss

Showing results (331-340 of 419) with videos related to

Pageof 42
Sort By:
Molecular Cancer Research : MCR|May 27, 2021
High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and PembrolizumabChung-Han Lee, Renzo G DiNatale, Diego Chowell, et al.
European Urology Focus|July 30, 2017
Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell CarcinomaBrandon John Manley, Emily C Zabor, Jozefina Casuscelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2021
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapiesD M Barrios, G S Phillips, A N Geisler, et al.
Science (New York, N.Y.)|January 6, 2018
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinomaDiana Miao, Claire A Margolis, Wenhua Gao, et al.
Nature Communications|October 8, 2016
Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsetsYing-Bei Chen, Jianing Xu, Anders Jacobsen Skanderup, et al.
European Urology|October 19, 2016
Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell CarcinomaJames J Hsieh, David Chen, Patricia I Wang, et al.
European Urology|November 5, 2025
MLH1 Mismatch Repair Deficiency Predicts Exceptional Response to Immune Checkpoint Inhibition in Clear-cell Renal Cell CarcinomaMark T Dawidek, Lina Posada Calderon, Parantu K Shah, et al.
European Urology Oncology|October 16, 2021
Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic TestingHong Truong, Rania Sheikh, Ritesh Kotecha, et al.
Genome Medicine|December 19, 2022
Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escapeMahdi Golkaram, Fengshen Kuo, Sounak Gupta, et al.
European Urology Focus|October 26, 2017
Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell CarcinomaMaria F Becerra, Ed Reznik, Almedina Redzematovic, et al.
Pageof 42

Showing results (331-340 of 419) with videos related to

Sort By:
Pageof 42
Molecular Cancer Research : MCR|May 27, 2021
High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and PembrolizumabChung-Han Lee, Renzo G DiNatale, Diego Chowell, et al.
European Urology Focus|July 30, 2017
Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell CarcinomaBrandon John Manley, Emily C Zabor, Jozefina Casuscelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2021
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapiesD M Barrios, G S Phillips, A N Geisler, et al.
Science (New York, N.Y.)|January 6, 2018
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinomaDiana Miao, Claire A Margolis, Wenhua Gao, et al.
Nature Communications|October 8, 2016
Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsetsYing-Bei Chen, Jianing Xu, Anders Jacobsen Skanderup, et al.
European Urology|October 19, 2016
Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell CarcinomaJames J Hsieh, David Chen, Patricia I Wang, et al.
European Urology|November 5, 2025
MLH1 Mismatch Repair Deficiency Predicts Exceptional Response to Immune Checkpoint Inhibition in Clear-cell Renal Cell CarcinomaMark T Dawidek, Lina Posada Calderon, Parantu K Shah, et al.
European Urology Oncology|October 16, 2021
Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic TestingHong Truong, Rania Sheikh, Ritesh Kotecha, et al.
Genome Medicine|December 19, 2022
Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escapeMahdi Golkaram, Fengshen Kuo, Sounak Gupta, et al.
European Urology Focus|October 26, 2017
Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell CarcinomaMaria F Becerra, Ed Reznik, Almedina Redzematovic, et al.
Pageof 42